Anti-GD2 Antibody Dinutuximab Beta and Low-Dose Interleukin 2 After Haploidentical Stem-Cell Transplantation in Patients With Relapsed Neuroblastoma: A Multicenter, Phase I/II Trial.
Tim FlaadtRuth Lydia LadensteinMartin EbingerHolger N LodeHelga Björk ArnardóttirUlrike PötschgerWolfgang SchwingerRichard P MeiselFriedhelm R SchusterMichaela DöringPeter F AmbrosManon QueudevilleJoerg FuchsSteven W WarmannJürgen Frank SchäferChristian SeitzPatrick SchlegelInes B BrechtUrsula HolzerTobias FeuchtingerThorsten SimonJohannes H SchulteAngelika EggertHeiko-Manuel TeltschikToni IllhardtRupert HandgretingerPeter LangPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)
DB therapy after haplo-SCT in patients with rHR-NB is feasible, with low risk of inducing GvHD, and results in long-term remissions likely attributable to increased antineuroblastoma activity by donor-derived effector cells.
Keyphrases
- stem cell transplantation
- high dose
- low dose
- induced apoptosis
- acute lymphoblastic leukemia
- cell cycle arrest
- acute myeloid leukemia
- clinical trial
- study protocol
- diffuse large b cell lymphoma
- dendritic cells
- phase iii
- multiple myeloma
- allogeneic hematopoietic stem cell transplantation
- phase ii
- regulatory t cells
- endoplasmic reticulum stress
- double blind
- type iii
- open label
- cell proliferation
- peripheral blood
- cell therapy
- replacement therapy